ClinicalTrials.Veeva

Menu

Continuous Adductor Canal Block (CACB) Combined With İnfiltration Between the Popliteal Artery and Capsule of the Knee (iPACK) Block vs Continuous Adductor Canal Block Alone After Total Knee Arthroplasty

B

Başakşehir Çam & Sakura City Hospital

Status

Not yet enrolling

Conditions

Postoperative Pain
Total Knee Arthroplasty

Treatments

Procedure: Continuous adductor canal block (CACB)
Procedure: IPACK block

Study type

Interventional

Funder types

Other

Identifiers

NCT07851506
BSH-ANES-MYM-02

Details and patient eligibility

About

This study compares the effects of adding an infiltration between the popliteal artery and capsule of the knee (iPACK) block to a continuous adductor canal block (CACB) versus continuous adductor canal block alone on postoperative analgesia, opioid consumption, early mobilization, and length of hospital stay in patients undergoing total knee arthroplasty. This is a prospective, randomized, double-blind study with 54 patients allocated 1:1 into two groups.

Full description

Severe postoperative pain occurs in up to 58% of patients after total knee arthroplasty. Peripheral nerve blocks are an effective component of multimodal analgesia, and the continuous adductor canal block (CACB) has become a preferred technique because it provides sensory blockade while sparing motor function of the quadriceps, allowing earlier ambulation compared to femoral nerve block. However, CACB does not address posterior knee pain, which can be targeted by the iPACK (infiltration between the popliteal artery and capsule of the knee) block, a technique that blocks terminal sensory branches of the tibial and peroneal nerves without motor blockade.

In this study, patients scheduled for total knee arthroplasty will be randomized 1:1 (using randomizer.org) to receive either CACB alone (Group 2) or CACB combined with a single-injection iPACK block (Group 1). CACB will be maintained via a perineural catheter connected to a patient-controlled analgesia (PCA) pump delivering 0.1% bupivacaine. Rescue analgesia will be provided with intravenous tramadol (50 mg, max 300 mg/day) when the numeric rating scale (NRS) pain score exceeds 4.

Pain scores (NRS 0-10), total analgesic and opioid consumption, hemodynamic parameters, time to first mobilization (assessed via the Timed Up and Go test), patient satisfaction, and length of hospital stay will be recorded at baseline and at 1, 3, 6, 12, and 24 hours postoperatively by an anesthesiologist blinded to group allocation, different from the anesthesiologist who performed the block.

Enrollment

54 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients of either sex
  • Aged 18 to 75 years
  • American Society of Anesthesiologists (ASA) physical status I, II, or III
  • Voluntary participation
  • Fully oriented and able to cooperate with postoperative assessments

Exclusion criteria

  • ASA physical status IV or V
  • Patients who decline to participate
  • Pediatric patients
  • Active infection at the block site
  • Chronic pain or regular analgesic use
  • Coagulation disorders
  • Inability to cooperate with postoperative pain assessment
  • Known allergy to local anesthetics
  • Neuropathy or myopathy in the operated extremity
  • Revision arthroplasty cases

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

54 participants in 2 patient groups

Group 1 (CACB + iPACK)
Experimental group
Description:
Continuous adductor canal block (catheter, PCA with 0.1% bupivacaine) plus a single-injection iPACK block (0.25% bupivacaine 20 mL)
Treatment:
Procedure: IPACK block
Procedure: Continuous adductor canal block (CACB)
Group 2 (CACB Alone)
Active Comparator group
Description:
Continuous adductor canal block alone (catheter, PCA with 0.1% bupivacaine)
Treatment:
Procedure: Continuous adductor canal block (CACB)

Trial contacts and locations

1

Loading...

Central trial contact

Furkan TONTU, MD; Muzaffer GENCER, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems